Troubled GenVec decides to stay in business; ThromboGenics inks ophthalmic R&D pact with Bicycle Therapeutics;

@FierceBiotech: Troubled Rigel axes 30 staffers as it maps a comeback R&D strategy. Story | Follow @FierceBiotech

@JohnCFierce: Trending on FierceBiotech: In big setback, GlaxoSmithKline's cancer immunotherapy MAGE-A3 flunks PhIII goal. Article | Follow @JohnCFierce

@RyanMFierce: In growing diabetes market, Sanofi looks beyond iPhone for mobile glucose testing. More from FierceBiotechIT | Follow @RyanMFierce

@EmilyMFierce: Matter: A Catalog for all the World's Viruses? More from the NY Times | Follow @EmilyMFierce

> Gaithersburg, MD-based GenVec ($GNVC) has reversed course on its plans to shutter the gene therapy company. The troubled biotech experienced a nasty setback when it reported that its lead therapy, TNFerade, failed a late-stage study for pancreatic cancer. But the company has since had a change of heart about its prospects for a hearing loss project partnered with Novartis ($NVS) in a $220 million deal. CEO Cynthia Collins, meanwhile, has exited the company and been replaced by CFO Douglas J. Swirsky. GenVec shares ended the day yesterday at 48 cents. Story

> Belgium's ThromboGenics has struck a deal with the U.K.'s Bicycle Therapeutics to develop and commercialize new ophthalmic drugs for a variety of conditions, including diabetic macular edema. Release

> South San Francisco-based Theravance ($THRX) reported positive topline results from a dose-ranging 7-day crossover-design Phase IIb study of its LAMA TD-4208. Release

Medical Device News

@FierceMedDev: Siemens Dx test panel recall draws FDA's "most serious" label. Story | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has some great new stories--check them out! FierceDiagnostics | Follow @MarkHFierce

@MichaelGFierce: Laser system gives clear, real-time image of brain tumors for surgery. Item | Follow @MichaelGFierce

> Edwards says diabetes patients may benefit from Sapien heart valve. More

> Echo Therapeutics to meet with angry shareholder. Article

> Philips joins effort to test "focused ultrasound" against metastatic bone cancer. News

Pharma News

@FiercePharma: ICYMI: Yesterday's top story: Onyx CEO will score $58M on Amgen deal. Other execs also to collect millions. More | Follow @FiercePharma

@EricPFierce: New AstraZeneca aseptic manufacturing facility at Macclesfield would add 3 dozen jobs. News | Follow @EricPFierce

@CarlyHFierce: From FierceVaccines: Will increased #flushot options confuse patients? Story Follow @CarlyHFierce

> With $886M Astex buy, Otsuka joins Japanese rivals in overseas dealmaking. More

> Eli Lilly expects no clarity on Alimta monopoly till 2014. Story

> EU leaders slam China for targeting foreign drugmakers. Article

Pharma Manufacturing News

> PhRMA, BIO, GPhA lose suit against drug-disposal law. More

> AstraZeneca plant expansion would add 3 dozen jobs. Story

> Mylan expansions roll on. Article

> Plant in Spain gets warning letter for failing to test products. News

> Merck plant gets FDA nod for bulk varicella. Report

> Last-mile thefts grow dramatically this year. Item

Vaccines News

> PATH defends itself against Indian criticisms of HPV project. Story

> CDC reports strong uptake of Merck's Gardasil in boys. More

> Researchers promise renewed push to build on Thai HIV trial success. Article

> Doctors warn plethora of flu vaccines may confuse patients. News

> FDA clears Merck plant to produce shingles vaccine ingredient. Report

> Israel may drop planned HPV vaccination program. Item

And Finally... A new study finds that hospitals are able to command a wide range of reimbursements from insurers, depending on their market clout. Story

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.